Invention Grant
- Patent Title: Cancer treatment with endothelin receptor antagonists
- Patent Title (中): 用内皮素受体拮抗剂治疗癌症
-
Application No.: US13949895Application Date: 2013-07-24
-
Publication No.: US09125897B2Publication Date: 2015-09-08
- Inventor: Robert Schneider , Sumayah Jamal
- Applicant: New York University
- Applicant Address: US NY New York
- Assignee: NEW YORK UNIVERSITY
- Current Assignee: NEW YORK UNIVERSITY
- Current Assignee Address: US NY New York
- Agency: Leason Ellis LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K38/00 ; C07K14/575 ; G01N33/50 ; G01N33/574 ; G01N33/74 ; A61K31/7088
Abstract:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
Public/Granted literature
- US20130309253A1 CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS Public/Granted day:2013-11-21
Information query
